• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Clinial Relevance of Novel Angiotensin II Generation Pathway within the Kidney

Research Project

Project/Area Number 10671004
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Kidney internal medicine
Research InstitutionKeio University

Principal Investigator

HAYASHI Koichi  Keio University, School of Medicine, Assistant Professor, 医学部, 講師 (80164937)

Co-Investigator(Kenkyū-buntansha) TOKUYAMA Hirobumi  Keio University, School of Medicine, Assistant, 医学部, 助手 (50276250)
HONDA Masanori  Keio University, School of Medicine, Assistant, 医学部, 助手 (20270514)
久保田 英司  慶應義塾大学, 医学部, 助手 (40255451)
松田 洋人  慶應義塾大学, 医学部, 助手 (80245498)
Project Period (FY) 1998 – 1999
Project Status Completed (Fiscal Year 1999)
Budget Amount *help
¥3,000,000 (Direct Cost: ¥3,000,000)
Fiscal Year 1999: ¥1,200,000 (Direct Cost: ¥1,200,000)
Fiscal Year 1998: ¥1,800,000 (Direct Cost: ¥1,800,000)
Keywordsangiotensin converting enzyme inhibitors / angiotensin receptor antagonists / kidney / afferent arterioles / efferent arterioles / renal hemodynamics / アンジオテンシン変換酵素阻害薬
Research Abstract

Since the development of angiotensin receptor antagonists (AIIA), it has been a matter of controversy whether ACE-I is more effective than AIIA in retarding the progression of renal disease. The present study was conducted to elucidate whether the accumulation of bradykinin contributes to the ACE-I action, and whether non-ACE-mediated angiotensin II generation participates in the renal protection of these agents. Using intravital CCD camera technique, an angiotensin receptor antagonist (E4177) dilated different (AFF) and efferent arterioles (EFF), in superficial nephrons (SP) and juxtamedullary nephrons (JM). Subsequently, cilazaprilat caused further dilation of both AFF and EFF in JM, whereas in SP it dilated only EFF. These cilazaprilat-induced vasodilation and natriuresis were abolished by a bradykinin antagonist. In parallel with these results, cilazaprilat increased renal bradykinin contents, greater in the medulla than in the cortex. Next, angiotensin II generation via ACE-mediat … More ed and non-ACE-mediated pathways was examined. The ratio of ACE/non-ACE-mediated ANG II generation was 8:2 in dog renal cortex, whereas in the heart this value proved to be 4:6. In the kidney, when compared with the effects of intrarenally administered ANG I and [ProィイD111ィエD1, D-AlaィイD112ィエD1]-ANGI (S) (an ANGI analog that cannot be converted to ANG II by ACE) on systemic blood pressure (BP) and renal blood flow (RBF), S required 100-fold higher concentrations to obtain the same degree of changes in BP and RBF. Further studies using intravital needle-type CCD camera microscopy demonstrated that renal afferent and efferent arteriolar actions of S were diminished, compared with those of ANGI. S at a dose of 100 nmol caused 30% decrements in RBF, which was completely abolished by g ANG receptor antagonist, but was only 50% inhibited by chymostatin. Finally, the comparison of the efficacy of chronic ACE-I and AllA treatment was made. In contrast to the acute study, intrarenal bradykinin contents were nearly the same in renal tissues from ACE-I-and AIIA-treated dogs. In conclusion, zonal heterogeneity in renal bradykinin levels and segmental differences in reactivity to bradykinin contribute to the diverse responsiveness of renal afferent and efferent arterioles to acute administration of ACE-I; ACE-I-enhanced kinin action would participate in glomerular hemodynamic changes by ACE-I. Futhermore, non-ACE activity, compared with ACE activity, contributes less to the renal ANG II generation, and chymase-mediated ANG II generation shares only half of the non-ACE-mediated ANG II production. Chronic treatment, however, fails to demonstrate the benefit of ACE-I-induced intrarenal bradykinin accumulation in protecting renal injury. Less

Report

(3 results)
  • 1999 Annual Research Report   Final Research Report Summary
  • 1998 Annual Research Report
  • Research Products

    (20 results)

All Other

All Publications (20 results)

  • [Publications] Matsuda H: "Role of bradykinin in angiotensin converting enzyme inhibitor induced dilation of renal microvessels in vivo."Journal of Hypertension. 16. s136 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] Matsuda H: "Potential role of endthelium-derived hyperpolarizing factor (EDHF) induced by ACE-I in renal microcirculation in vivo"Journal of Ameircan Society of Nephrology. 9. 342 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] 林晃一: "アンジオテンシンII受容体拮抗薬の臨床:腎疾患治療薬としての臨床応用の展望"日本臨床. 57(5). 164-167 (1999)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] Matsuda H: "Zonal heterogeneity induced dilation in action of angiotensin-converting enzyme inhibitor on renal microcirculation: role of intrarenal bradykinin"Journal of American Society of Nephrology. 10. 2272-2282 (1999)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] 林晃一: "腎微小循環におけるアンジオテンシンII作用の新知見"診断と新薬. 36(3). 205-208 (1999)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] Murakami M, et al.: "Role of angiotensin II generated by angiotensin converting enzyme-independent pathways in canine kidney."Kidney Int. 52. s132-s135 (1997)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] Murakami M, et al.: "Role ofangiotensin II generated by an ACE independent pathway in canine kidney"Nephrology. 3. S53 (1997)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] Takenaka T, et al.: "Cellular mechanisms mediating rat renal microvascular constriction by angiotensin II."J Clin Invest. 100. 2107-2114 (1997)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] Saruta T, et al.: "Recent treament of hypertension in Japan"Am J Cardiol. 82. 32-34 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] Ozawa Y; et al.: "Renal afferent and efferent arteriolar dilation by nilvadipine: studies in the isolated perfused hydronephrotic kidney"J Cardiovasc Pharmacol. 33. 243-247 (1999)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] Matsuda H, et al.: "Zonal heterogeneity in action of angiotensin-converting enzyme inhibitor on renal microcirculation: role of intrarenal bradykinin"J Am Soc Nephrol. 10(11). 2272-2282 (1999)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] Hayashi K, et al.: "Potential role of angiotensin receptor antagonists in renal protection."Nippon Rinsho. 57(5). 1164-1167 (1999)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] Matsuda H: "Zonal heterogeneity induced dilation in action of angiotensin-converting enzyme inhibitor on renal microcirculation:role of intrarenal bradykinin"Journal of American Society of Nephrology. 10. 2272-2282 (1999)

    • Related Report
      1999 Annual Research Report
  • [Publications] 林 晃一: "アンジオテンシンII受容体拮抗薬の臨床:腎疾患治療薬としての臨床応用の展望"日本臨床. 57(5). 164-167 (1999)

    • Related Report
      1999 Annual Research Report
  • [Publications] 林 晃一: "腎内血行動態のヘテロジェネイティ"日本臨床生理学会雑誌. 29(suppl). 51 (1999)

    • Related Report
      1999 Annual Research Report
  • [Publications] 林 晃一: "腎微小循環におけるアンジオテンシンII作用の新知見"診断と新薬. 36(3). 205-208 (1999)

    • Related Report
      1999 Annual Research Report
  • [Publications] Matsuda H: "Role of bradykinin in angiotensin converting enzyme inhibitor induced dilation of renal microvessels in vivo" Journal of Hypertension. 16. s136 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] Matsuda H: "Potential role of endothelium-derived hyperpolarizing factor(EDHF)induced by ACE-I in renal microcirculation in vivo." Journal of American Society of Nephrology. 9. 342 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] 林 晃一: "腎障害を有する高血圧に対するACE阻害薬とAII拮抗薬:アンジオテンシン変換酵素とアンジオテンシン受容体拮抗薬" 循環器科. 43. 38-44 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] 林 晃一: "腎疾患におけるAII拮抗薬とACE阻害薬の比較" 血圧. 5. 577-578 (1998)

    • Related Report
      1998 Annual Research Report

URL: 

Published: 1998-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi